The deal is expected to close in late Q2 2025, subject to Nevro shareholder and regulatory approval.Globus Medical also reaffirmed its guidance for 2025 net sales of $2.66B to $2.69B and non-GAAP ...

As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor is the company holding an earnings conference call ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Globus Medical (GMED – Research Report) and Nevro Corp (NVRO – Research Report). See what stocks are receiving ...

2025 Financial Guidance and Fourth-Quarter 2024 Earnings Conference Call and Webcast As previously announced on February 6, 2025, given the pending acquisition of Nevro by Globus Medical ...

Following the consummation of the Nevro Corp. acquisition, which we expect to close late in the second quarter of 2025, Globus Medical anticipates 2025 net sales of $2.8 billion to $2.9 billion ...

Globus Medical's results underscore a strong quarter ... This outlook could improve further if the pending acquisition of Nevro (purchased for $250 million earlier this month) is finalized ...

In a surprising move, Globus Medical announced the acquisition of Nevro Corp . (NYSE:NVRO) for $250 million. While initially met with investor skepticism, analysts view this deal as potentially ...